Trevi Therapeutics
(NASDAQ) TRVI
Trevi Therapeutics Financials at a Glance
Market Cap
$1.94B
Revenue (TTM)
$0.00
Net Income (TTM)
$42.76M
EPS (TTM)
$-0.32
P/E Ratio
-43.08
Dividend
$0.00
Beta (Volatility)
0.78 (Low)
Dividend
$0.00
Beta (Volatility)
0.78 (Low)
Price
$13.77
Volume
95,969
Open
$14.05
Price
$13.77
Volume
95,969
Open
$14.05
Previous Close
$13.77
Daily Range
$13.11 - $14.05
52-Week Range
$5.38 - $16.12
Dividend
$0.00
Beta (Volatility)
0.78 (Low)
Price
$13.77
Volume
95,969
Open
$14.05
Previous Close
$13.77
Daily Range
$13.11 - $14.05
52-Week Range
$5.38 - $16.12
TRVI News
TRVI: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Trevi Therapeutics
Industry
Pharmaceuticals
Sector
Health CareEmployees
34
CEO
Jennifer L. Good, CPA
Website
www.trevitherapeutics.comHeadquarters
New Haven, CT 06510, US
TRVI Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-30%
Return on Capital
-27%
Return on Assets
-22%
Earnings Yield
-2.32%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.94B
Shares Outstanding
140.19M
Volume
95.97K
Avg. Volume
1.46M
Financials (TTM)
Gross Profit
$132.00K
Operating Income
$49.33M
EBITDA
$49.33M
Operating Cash Flow
$42.09M
Capital Expenditure
$12.00K
Free Cash Flow
$42.10M
Cash & ST Invst.
$188.26M
Total Debt
$753.00K
Trevi Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$31.00K
+18.4%
Gross Margin
0.00%
N/A
Market Cap
$1.94B
N/A
Market Cap/Employee
$62.50M
N/A
Employees
31
N/A
Net Income
$8.32M
+27.1%
EBITDA
$10.19M
+10.3%
Quarterly Fundamentals
Net Cash
$187.51M
+75.9%
Accounts Receivable
$986.00K
+85.3%
Inventory
$0.00
N/A
Long Term Debt
$446.00K
-40.3%
Short Term Debt
$307.00K
+7.7%
Return on Assets
-22.10%
N/A
Return on Invested Capital
-26.85%
N/A
Free Cash Flow
$5.85M
+161.2%
Operating Cash Flow
$7.63M
+20.1%